Real-World Evidence of Tirzepatide in Indian Adults With Type 2 Diabetes: Significant Early Glycemic and Cardiometabolic Benefits

In routine clinical practice, tirzepatide was associated with substantial glycemic improvement and meaningful weight loss at 12 weeks, along with favorable changes in cardiometabolic risk factors (blood pressure, lipids, hepatic indices). While the safety profile was consistent with global clinical trial data, real-world treatment persistence was significantly influenced by tolerability and affordability, highlighting important context-specific barriers in the Indian healthcare setting. Cost remains a key barrier to long-term use.